

ASX ANNOUNCEMENT

ASX: 1AI | 20 October 2025

Highlights

- **Algorae executes binding term sheet with Cadila Pharmaceuticals for Australian and New Zealand markets**
- **Strategic partnership expands Algorae's commercial footprint**

AI-enabled pharmaceutical company Algorae Pharmaceuticals Ltd (ASX: 1AI) ('Algorae' or 'the Company') is pleased to announce it has entered into a binding term sheet with **Cadila Pharmaceuticals Limited**, one of India's largest privately held pharmaceutical companies, for a proposed license and supply agreement.

Under the proposed agreement, Algorae will launch two generic medicines in the Australian and New Zealand markets, targeting key therapeutic areas including cardiovascular and metabolic disorders.

Both companies will now work towards executing a definitive License and Supply Agreement ('LSA'), which will formalise the operational framework of the partnership. Following execution of the LSA, Algorae will commence Therapeutic Goods Administration ('TGA') registration planning and documentation to enable product commercialisation and will update shareholders on approval timelines and anticipated revenue contributions as the program advances.

Cadila Pharmaceuticals, headquartered in Ahmedabad, India, operates manufacturing facilities accredited by global regulators including the US FDA, EU, MHRA (UK), WHO, and TGA. Its products are distributed in over 100 countries and supported by a workforce of more than 9,000 professionals. Algorae representatives recently met with senior management and technical teams at Cadila's Ahmedabad headquarters.

*"This partnership represents an important step in executing our commercial strategy and expanding our product portfolio through a world-class manufacturing partner," said **Chief Commercial Officer, Mr Vishal Shah**. "Our focus now is on finalising the definitive agreement and preparing for regulatory submissions."*

Algorae continues to progress a number of commercial and partnership initiatives and will provide further updates to shareholders as these developments advance.

About Cadila Pharmaceuticals Limited

Cadila Pharmaceuticals Limited is one of India's largest privately held pharmaceutical companies, with vertically integrated operations across active pharmaceutical ingredients ('APIs'), finished formulations, contract research, and manufacturing services. Headquartered in Ahmedabad, Gujarat, Cadila operates state-of-the-art facilities accredited by leading global regulators including the US FDA, EU, MHRA (UK), WHO and TGA. The Company's

products are marketed in over 100 countries across Asia, Africa, Europe and the Americas, supported by a global workforce of more than 9,000 professionals. Its research and development division comprises over 350 scientists working across key therapeutic areas such as respiratory, cardiometabolic, gastrointestinal, oncology, anti-infective and pain management.

Founded in 1951 by the late Indravadan A. Modi, Cadila has built a long-standing reputation for combining scientific innovation with social responsibility. Guided today by Dr Rajiv Modi, Chairman and Managing Director, the Company continues to advance its founding mission of "affordable innovation" through the discovery, development and global distribution of high-quality medicines. With a diversified portfolio, strong regulatory track record and commitment to sustainable growth, Cadila Pharmaceuticals remains a trusted partner in improving access to healthcare worldwide.

Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd

END.

Corporate and Media Enquiries

Mr. Brad Dilkes – Director

P: +61 422 180 317

E: brad@algoraepharma.com

About Algorae Pharmaceuticals

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical development company pioneering drug synergy discovery and development for unmet medical needs. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations with transformative therapeutic potential. Algorae collaborates with leading research institutions and pharmaceutical partners to accelerate the translation of AI-predicted therapies into the clinic.


Algorae intends to expand its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform. Known as Algorae Operating System (AlgoraeOS), the AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the aim of AlgoraeOS is to uncover synergistic drug combinations that lead to the development of novel and effective treatments for any medical condition, aligning with Algorae's commitment to address unmet medical needs. Algorae is listed and publicly traded on the Australian Stock Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical



ALGORAE
PHARMACEUTICALS

data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.